Clinical Oncology News: SABCS 2016: Everolimus Added to Fulvestrant Upped PFS in Postmenopausal HR+ Breast Ca Pts

December 1, 2016

Adding everolimus to fulvestrant in postmenopausal women with hormone receptor (HR)-positive/HER2-negative, aromatase inhibitor (AI)-resistant metastatic breast cancer improved progression-free survival (PFS) to 10.4 months, compared with 5.1 months for fulvestrant alone, in the randomized, double-blind, Phase II PrECOG 0102 trial. Read the full  story at Clinical Oncology News

Cancer Network: Chemo Plus Veliparib Improves Responses in BRCA-Mutant Breast Cancer

December 1, 2016

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy significantly increased response rates among women with BRCA1 or BRCA2 mutations and locally recurrent or metastatic breast cancer, according to a randomized phase II trial. Read the full story at Cancer Network

KMIZ 17: Stages of breast cancer

December 1, 2016

Accurate assessment of the extent of disease, or Stage, at the time of diagnosis, is one determinant of prognosis or risk of future recurrence of the cancer, and also determines ideal initial treatment. Read the full story at KMIZ 17

Express-News: International scientists and physicians bring latest breast cancer research to San Antonio

November 18, 2016

About 7,500 of the world’s leading breast cancer experts have made their way to San Antonio this week to unveil their latest diagnostic and treatment discoveries. Read the full story at the Express-News